Safety and Early Signs of Efficacy of IL12-L19L19.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumor
- DLBCL
- Metastatic Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Intervention Model: Sequential AssignmentIntervention Model Description: Prospective, open-label, non-randomized, multiple ascending dose, phase I dose escalation trial in patients with advanced solid carcinomas and DLBCL after previous immune-checkpoint blockade therapy conducted in sequential cohorts of patients followed by a dose expansion part.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04471987
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon